Deborah J. Anderson

Dr. Deborah J. Anderson is a Professor at Boston University Chobanian & Avedisian School of Medicine with dual appointments in the Department of Obstetrics & Gynecology and the Department of Virology, Immunology & Microbiology. She maintains strong affiliations with Boston University Medical Campus (BMC) and is a leading researcher in reproductive immunology and HIV prevention.

Her research program focuses on mucosal immunology at genital tract surfaces, with particular emphasis on understanding immune defense mechanisms against sexually transmitted pathogens. Key research areas include:

• Development of vaccines and topical microbicides for controlling HIV-1 and other sexually transmitted infections
• Mechanisms of cell-associated HIV transmission at genital mucosal surfaces
• Development of monoclonal antibody-based contraceptive technologies
• Investigation of the vaginal microbiome and its interactions with immune defenses
• Engineering of bispecific antibodies for non-hormonal contraception

Analysis of Dr. Anderson's 15 most recent publications (2021-2025) reveals a clear trajectory toward translational applications of basic immunological discoveries. Her work demonstrates increasing focus on antibody-based multipurpose prevention technologies (MPTs) that combine contraception with HIV prevention. Notable trends include the advancement of the Human Contraceptive Antibody (HCA) through clinical development, innovative formulations of bioadhesive vaginal films for extended antibody release, and pioneering exploration of mRNA-mediated reversible immunocontraception approaches. Her publications span high-impact journals including Science, Journal of Infectious Diseases, and PLoS Medicine, reflecting the significance of her contributions to both basic science and clinical applications.

Dr. Anderson has secured substantial research funding as Principal Investigator on multiple NIH grants, including:

• "Antibody-based Contraceptive MPTs: Advancing the Human Contraceptive Antibody (HCA) through Clinical Trials" (2023-2026, $3.2M)
• "Development of antisperm antibody-containing penile tubes and bioadhesive films for male contraception" (2023-2025, $750K)
• "Engineering bispecific antibodies for non-hormonal contraception" (2021-2025, $1.8M)
• "Synthetic mRNA-Mediated Reversible Immunocontraception" (2021-2024, $1.5M)

She serves as a primary mentor for graduate students through Boston University's Graduate Medical Sciences program and leads a multidisciplinary research team comprising immunologists, virologists, and reproductive biologists. Her laboratory maintains active collaborations with Boston Medical Center, Fenway Health, and industry partners including Mucommune LLC and MatTek Corporation to advance promising technologies toward clinical application.